Literature DB >> 8149358

Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study.

F Stocchi1, N P Quinn, L Barbato, P N Patsalos, M T O'Connel, S Ruggieri, C D Marsden.   

Abstract

After overnight drug withdrawal and in the fasting state, 11 patients with Parkinson's disease (PD) and a fluctuating response to chronic levodopa treatment were given, in random sequence on consecutive days, equivalent levodopa doses (with peripheral decarboxylase inhibitor) (a) as levodopa methyl ester (ME), (b) as Sinemet CR, or (c) as half the dose of ME together with a halved tablet of Sinemet CR. All patients turned ON rapidly after treatments a and c, but only half did so after treatment b. On period duration was longest after treatment c, intermediate after treatment a, and shortest after treatment b. Pharmacokinetic analysis in a subset of 6 patients revealed no significant difference between treatments a and c, although there was a trend for t1/2 to be longer after treatment c. We conclude that giving ME with a halved tablet of Sinemet CR provided a useful clinical balance between rapid onset and extended duration of action of at least the first levodopa intake of the day. In view of differing release profiles between whole and halved tablets of Sinemet CR, similar single-dose pharmacokinetic studies, followed by sequential-dose clinical studies, are indicated when Sinemet CR 125 tablets soon become available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149358     DOI: 10.1097/00002826-199402000-00004

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  10 in total

1.  Sustained-release of levodopa: single dose study of a new formulation.

Authors:  M Gerlach; W Kuhn; T Müller; P Klotz; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus.

Authors:  A Stefani; E Fedele; J Vitek; M Pierantozzi; S Galati; F Marzetti; A Peppe; M S Bassi; G Bernardi; P Stanzione
Journal:  Cell Death Dis       Date:  2011-05-05       Impact factor: 8.469

3.  Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Authors:  Cheryl H Waters; Paul Nausieda; Lyudmila Dzyak; Joerg Spiegel; Monika Rudzinska; Dee E Silver; Elena S Tsurkalenko; Sherron Kell; Ann Hsu; Sarita Khanna; Suneel Gupta
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

4.  Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes.

Authors:  Julia M Tan; Jhi Biau Foo; Sharida Fakurazi; Mohd Zobir Hussein
Journal:  Beilstein J Nanotechnol       Date:  2015-01-22       Impact factor: 3.649

5.  Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.

Authors:  Hsuan-Ming Yao; Ann Hsu; Suneel Gupta; Nishit B Modi
Journal:  Clin Neuropharmacol       Date:  2016 Jan-Feb       Impact factor: 1.592

Review 6.  Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.

Authors:  Aravind Mittur; Suneel Gupta; Nishit B Modi
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

Review 7.  Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Authors:  Alberto J Espay; Fernando L Pagan; Benjamin L Walter; John C Morgan; Lawrence W Elmer; Cheryl H Waters; Pinky Agarwal; Rohit Dhall; William G Ondo; Kevin J Klos; Dee E Silver
Journal:  Neurol Clin Pract       Date:  2017-02

8.  Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.

Authors:  Paul A Nausieda; Ann Hsu; Lawrence Elmer; Ramon A Gil; Joerg Spiegel; Carlos Singer; Sarita Khanna; Robert Rubens; Sherron Kell; Nishit B Modi; Suneel Gupta
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 9.  Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.

Authors:  Jason Margolesky; Carlos Singer
Journal:  Ther Adv Neurol Disord       Date:  2017-10-30       Impact factor: 6.570

10.  Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease.

Authors:  Masahiro Nomoto; Masahiro Nagai; Noriko Nishikawa; Rina Ando; Yoshifumi Kagamiishi; Koji Yano; Shigeto Saito; Atsushi Takeda
Journal:  eNeurologicalSci       Date:  2018-09-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.